Stocktoria
RHYTHM PHARMACEUTICALS, INC. RYTM
RHYTHM PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $167.3M | $238.0M | $135.0M | $108.6M | $104.1M | $90.5M | $109.5M | $50.3M | $22.9M | $19.6M |
| SG&A expense | $194.9M | $144.3M | $117.5M | $92.0M | $68.5M | $46.1M | $36.5M | $28.1M | $9.5M | $6.3M |
| Operating income | -$192.0M | -$265.5M | -$184.4M | -$179.2M | -$170.1M | -$136.6M | -$146.0M | -$78.4M | -$32.4M | -$25.9M |
| Interest expense | — | — | $13.9M | $5.2M | — | — | — | — | — | — |
| Income tax | $497,000 | $346,000 | $564,000 | — | — | — | — | — | — | — |
| Net income | -$196.5M | -$260.6M | -$184.7M | -$181.1M | -$69.6M | -$134.0M | -$140.7M | -$74.1M | -$33.7M | — |
| EPS (diluted) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 | — | — | — |
| Operating cash flow | -$115.7M | -$113.9M | -$136.2M | -$173.4M | -$146.0M | -$122.0M | -$122.8M | -$62.1M | -$29.5M | -$23.2M |
| Free cash flow | -$116.6M | -$113.9M | -$136.2M | -$173.7M | -$146.4M | -$122.2M | -$126.1M | -$62.8M | -$29.6M | -$24.3M |
| Cash & equivalents | $54.3M | $89.1M | $60.1M | $127.7M | $59.2M | $100.9M | $62.3M | $49.5M | $34.2M | $6.5M |
| Inventory | $25.8M | $18.7M | $8.6M | $2.9M | $111,000 | — | — | — | — | — |
| Total assets | $480.2M | $392.3M | $332.7M | $382.5M | $329.5M | $187.1M | $308.5M | $260.2M | $151.7M | $12.3M |
| Total liabilities | $210.2M | $227.7M | $163.0M | $118.2M | $45.4M | $20.5M | $27.5M | $14.0M | $6.9M | $5.0M |
| Shareholders' equity | $139.1M | $21.7M | $169.8M | $264.3M | $284.2M | $166.5M | $281.0M | $246.3M | $144.8M | -$32.7M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +45.8% | +68.1% | +227.6% | +649.5% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.